Abstracts tagged "ocular involvement and tocilizumab"

Abstract Number: 2755 • 2018 ACR/ARHP Annual Meeting
Utility of Tocilizumab in Visual Affection of Patients with Giant Cell Arteritis
Monica Calderón Goercke¹, Javier Loricera², Diana Prieto Peña¹, Clara Moriano Morales³, Elvira Diez Alvarez⁴, Francisco Javier Narváez⁵, Antonio Mera⁶, Eva Perez Pampín⁶, Vicente Aldasoro⁷, María Varela-García⁸, Noelia Álvarez-Rivas⁹, Ceferino Barbazan¹⁰, Carmen Ordas-Calvo¹¹, Francisca Sivera¹², Cristina Luna Gómez¹³, Francisco J. Toyos Sáenz de Miera¹⁴, Arantxa Conesa¹⁵, Francisco Navarro¹⁶, Belén Atienza-Mateo¹⁷, José Luis Martín-Varillas¹⁷, Eva Galindez-Agirregoikoa¹⁸, Vanesa Calvo-Río¹⁷, Carmen González-Vela¹⁹, Natalia Palmou-Fontana², José Luis Hernández², Miguel Angel González-Gay² and Ricardo Blanco¹⁷, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, ⁶Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ⁷Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁸Complejo Hospitalario de Navarra, Navarra, Spain, ⁹Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, ¹¹Hospital Cabueñes, Gijón. Spain, Gijón, Spain, ¹²Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹³Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, ¹⁴Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, ¹⁵Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, ¹⁶Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, ¹⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁸Rheumatology, University Hospital of Basurto, Bilbao, Spain, ¹⁹Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with a special predilection for extracranial branches of the external carotid artery. Among its most…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].